Сonfirmatory study of the efficacy and tolerability of trifluridine/tipiracil (TAS-102) therapy in the Russian population with chemorefractory metastatic colorectal cancer

Introduction. Trifluridine/Tipiracil (FTD/TPI) is a new chemotherapeutic drug approved in more than 60 countries for use in patients with metastatic colorectal cancer who have registered progression or intolerance to treatment with fluoropyrimidines, oxaliplatin and irinotecan, anti-VEGRand anti-EGF...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Glavni autori: M. Yu. Fedyanin, F. V. Moiseenko, D. A. Chekini, V. A. Chubenko, A. S. Zhabina, L. A. Zagorskaya, M. M. Kramchaninov, S. A. Tjulandin, V. M. Moiseyenko
Format: Artigo
Jezik:Russo
Izdano: Remedium Group LLC 2020-12-01
Serija:Медицинский совет
Teme:
trifluridine/tipiracil
tas-102
metastatic cancer
colorectal
chemotherapy
targeted therapy
Online pristup:https://www.med-sovet.pro/jour/article/view/5934
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items